The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
High Incidence of ActivatingTERTPromoter Mutations in Meningiomas Undergoing Malignant Progression
Open accessAbstract
Meningiomas are common central nervous system tumors. The World Health Organization (WHO) defines three grades, predictive of the risk of recurrence. These tumors can relapse frequently and sometimes undergo malignant transformation. Maintenance of telomere length is a key process in malignant progression, and mutations inTERTpromoter have recently been identified in various types of cancer. We sequenced theTERTpromoter in 85 meningiomas from 73 patients. We found a high incidence ofTERTpromoter mutations in patients with meningiomas undergoing malignant histological progression (28%, n = 5/18 patients). In this subset of patients with histological progression,TERTpromoter mutations were found in both the lowest and the highest grade tumors, and in bothNF2‐mutated and nonmutated samples. In contrast, one mutation was identified in 35 meningiomas without recurrence or progression, belonging to various histological grades. This sample was an aggressive meningioma in a patient who died shortly after surgery. Interestingly, tumors showing relapse without histological progression were not mutated forTERTpromoter (n = 20). Finally,TERTpromoter mutations were associated with a marked increase inTERTexpression. Thus,TERTpromoter mutations are pivotal genetic alterations involved in malignant progression of meningiomas and could be used as a biomarker to identify meningiomas at risk of malignant transformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Cited by
EANO guidelines for the diagnosis and treatment of meningiomas
Goldbrunner, R., Minniti, G., Preusser, M., Jenkinson, M. D., Sallabanda, K., Houdart, E., von Deimling, A., Stavrinou, P., Lefranc, F., Lund-Johansen, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30321-7 · Cited by 854
Sahm, F., Schrimpf, D., Stichel, D., Jones, D. T. W., Hielscher, T., Schefzyk, S., Okonechnikov, K., Koelsche, C., Reuss, D. E., Capper, D., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30155-9 · Cited by 852
EANO guideline on the diagnosis and management of meningiomas
Goldbrunner, R., Stavrinou, P., Jenkinson, M. D., Sahm, F., Mawrin, C., Weber, D. C., Preusser, M., Minniti, G., Lund-Johansen, M., Lefranc, F., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab150 · Cited by 742
Role of Merlin/NF2 inactivation in tumor biology
Petrilli, A. M., & Fernández-Valle, C. (2016) · Oncogene · doi:10.1038/onc.2015.125 · Cited by 458
TERT Promoter Mutations and Risk of Recurrence in Meningioma
Sahm, F., Schrimpf, D., Olar, A., Koelsche, C., Reuss, D., Bissel, J., Kratz, A., Capper, D., Schefzyk, S., Hielscher, T., et al. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv377 · Cited by 406
Metadata
- Authors
- Goutagny, S., Nault, J. C., Mallet, M., Henin, D., Rossi, J. Z., & Kalamarides, M.
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2013-12-23
- Volume
- 24
- Issue
- 2
- Pages
- 184-189
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- OpenAlex
- W1851839265
- Cited by
- 249
- References
- 1
- FWCI
- 9.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High Incidence of ActivatingTERTPromoter Mutations in Meningiomas Undergoing Malignant Progression. https://app.cochat.ai/papers/10.1111/bpa.12110
- The paper
- Goutagny, S., Nault, J. C., Mallet, M., Henin, D., Rossi, J. Z., & Kalamarides, M. (2014). High Incidence of ActivatingTERTPromoter Mutations in Meningiomas Undergoing Malignant Progression. Brain Pathology. https://doi.org/10.1111/bpa.12110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.